Search

Objective: A description of the protocol of organizational peculiarities of cohort composition and preliminary results of the using the model of TB treatment program under the control of responsible family member Family-DOT (F-DOT) for pediatric patients with drug-resistant (DR) forms of TB (DR-TB) in the Republic of Tajikistan. Methods: A descriptive analysis of existing MSF program data collected on eleven F-DOT patients between April 2017 and May 2018 is used. Results: Eleven eligible patients with a stable form of tuberculosis provided the F-DOT program after receiving their prior consent. At this moment, seven of them are continuing therapy, while four of them have successfully completed the treatment. Among the participants of the program are children aged 1 to 17 years old, 54.5% of girls and 54.5% of patients with extensively drug-resistant tuberculosis (XDR TB). Conclusion: Earlier empirical data and initial results show that there the possibility and viability is the use of models of therapy and home care for pediatric patients with DR-TB in the Republic of Tajikistan.

Aim. To evaluate the efficiency of chemotherapy with standard doses of melfalan and dexamethazone versus autologous peripheral hemopoietic cell transplantation (auto-PHCT) in patients with AL amyloidosis and to reveal poor prognostic factors. Subjects and methods. Of 36 patients diagnosed as having AL-amylodosis, 17 patients underwent auto-PHCT, 11 patients received chemotherapy only; 8 patients died prior to treatment. Results. In patients with AL-amyloidosis after chemotherapy and autotransplantation, 3-year overall survival was 28 and 64%, respectively. Low somatic ECOG status and cardiac lesion were independent poor prognostic factors of the disease. The number of involved organs failed to affect overall survival. Conclusion. Auto-PHCT may be proposed as first-line therapy for patients with AL-amyloidosis who have a somatic ECOG score of 0 to 2 and not more than 3 organs involved. Young patients who have a satisfactory somatic status and no benefit from autotransplantation may undergo auto-PHCT. It is expedient to use average-dose melfalan and dexamethasone when treating patients who are ineligible for high-dose chemotherapy.